Improving the treatment of hepatitis C infection in the UK

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 2, 2007, Pages 183-191

  Cooke, Graham S ^a   Main, Janice ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Hepatitis c virus; IFN 2a; IFN 2b; Interferon; Pegylated interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BAVITUXIMAB; CILUPREVIR; DIDANOSINE; INTERFERON; LEVOVIRIN; MERIMEPODIB; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAMIDINE; RIBAVIRIN; SCG 503034; STAVUDINE; TELAPREVIR; UNCLASSIFIED DRUG; VALOPICITABINE; VIRUS RNA; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INFECTION PREVENTION; LIVER BIOPSY; LIVER TRANSPLANTATION; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; PANCREATITIS; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS RESISTANCE;

ACUTE DISEASE; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DISEASE TRANSMISSION, VERTICAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; PATIENT SELECTION; TREATMENT FAILURE;

EID: 33846821730     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.2.183     Document Type: Review

References (72)

1. WHO: Hepatitis C- global prevalence (update). Weekly Epidemiology Record (1999) 74:425-427.
2. ADES AE, PARKER S, WALKER J et al.: HCV prevalence in pregnant women in the UK. Epidemiol, Infect. (2000) 125:399-405.
3. BALOGUN MA, RAMSAY ME, PARRY JV et al.: The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England. Epidemiol. Infect. (2000) 125:705-712.
4. BALOGUN MA, RAMSAY ME, HESKETH LM et al.: The prevalence of hepatitis C in England and Wales. J. Infect. (2002) 45:219-226.
5. HPA: Hepatitis C in England: the first Health Protection Agency annual report. Health Protection Agency Centre for Infections, London (2005).
6. ROSENBERG W: The UK v Europe: losing the fight against hepatitis C. The Hepatitis C Trust (2005).
7. DOH: Hepatitic C Action Plan for England. Department of Health, London (2004).
8. DOH: Hepatitis C strategy for England. Department of Health, London (2002).
9. NICE: Inteferon-α (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. Technology Appraisal 75. NHS (2004).
10. LAU DT, KLEINER DE, GHANY MG et al: 10-Year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology (1998) 28:1121-1127.
11. MARCELLIN P, BOYER N, GERVAIS A et al.: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann. Intern. Med. (1997) 127:875-881.
12. SORIANO V, MAIDA I, NUNEZ M et al.: Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir. Ther. (2004) 9:987-992.
13. TSUDA N, YUKI N, MOCHIZUKI K et al.: Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J. Med. Virol. (2004) 74:406-413.
14. HADZIYANNIS SJ, SETTE H, JR, MORGAN TR et al.: Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med (2004) 140:346-355.
15. FRIED MW, SHIFFMAN ML, REDDY KR et al.: Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. (2002) 347:975-982.
16. MANNS MP, MCHUTCHISON JG, GORDON SC et al.: Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358:958-965.
17. ZEUZEM S, HEATHCOTE EJ, SHIFFMAN ML et al.: Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis C. J. Hepatol. (2003) 39:106-111.
18. DAVIS GL, WONG JB, MCHUTCHISON JG et al.: Early virologic response to treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 38:645-652.
19. LIU LW, TOMLINSON G, MAZZULLI T et al.: Early prediction of nonresponders to treatment with interferon α-2b and ribavirin in patients with chronic hepatitis C. Can. J. Gastroenterol. (2003) 17:483-487.
20. ZEUZEM S, BUTI M, FERENCI P et al.: Efficacy of 24 weeks treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. (2006) 44:97-103.
21. MUIR AJ, BORNSTEIN JD, KILLENBERG PG: Peginterferon α-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med. (2004) 350:2265-2271.
22. SIDDIQUE I, EL-NAGA HA, MADDA JP et al.: Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand. J. Gastroenterol. (2003) 38:427-432.
23. SANDRIN L, FOURQUET B, HASQUENOPH JM et al.: Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol. (2003) 29:1705-1713.
24. FOUCHER J, CHANTELOUP E, VERGNIOL J et al.: Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut (2006) 55:403-408.
25. CASTERA L, VERGNIOL J, FOUCHER J et al.: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology (2005) 128:343-350.
26. BODENHEIMER HC Jr., LINDSAY KL, DAVIS GL et al.: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology (1997) 26:473-477.
27. DI BISCEGLIE AM, CONJEEVARAM HS, FRIED MW et al.: Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1995) 123:897-903.
28. SHIFFMAN ML: Treatment of chronic hepatitis C virus (HCV) genotype 1 with peginterferon α-2b (PEGIFN-), high weight based dose ribavirin (RVN) and Epoetin α (EPO) enhances sustained virological response (SVR). Presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco (2005).
29. SPIEGEL BM, CHEN K, CHIOU CF et al.: Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin. Gastroenterol. Hepatol. (2005) 3:1034-1042.
30. CASSARD B: Early predictive TDM of ribavirin in HIV-HCV coinfected patients. Presented at the 2nd International Workshop on HCV/HIV Coinfection (2006) Abstr. 26.
31. RAMOS B: High ribavirin doses and early virological response in HCV/HIV co-infected patients. Presented at the 2nd International Workshop on HCV/ HIV Coinfection (2006) Abstr. 36.
32. AUGUST-JORG BS, BOROVICKA J, DUFOUR JF et al.: Twenty-four versus forty-eight weeks of retherapy with interferon α 2b and ribavirin in interferon α monotherapy relapsers with chronic hepatitis C. Swiss Med. Wkly (2003) 133:455-460.
33. STEINDL-MUNDA P, FERENCI P, BRUNNER H et al.: Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy. Liver Int. (2003) 23:269-275.
34. MOSKOVITZ DN, MANOHARAN P, HEATHCOTE EJ: High dose consensus interferon in nonresponders to interferon α-2b and ribavirin with chronic hepatitis C. Can. J. Gastroenterol. (2003) 17:479-482.
35. POYNARD T, MARCELLIN P, BISSERY A et al.: Reinforced interferon α-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. J Viral Hepat. (2003) 10:197-204.
36. FARGION S, BRUNO S, BORZIO M et al.: Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon. J. Hepatol. (2003) 38:499-505.
37. HOOFNAGLE JH, GHANY MG, KLEINER DE et al.: Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon α and ribavirin. Hepatology, (2003) 38:66-74.
38. SHIFFMAN ML, DI BISCEGLIE AM, LINDSAY KL et al.: Peginterferon α-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 126:1015-1023.
39. BOUCHER EJ, JACQUELINET S, CANVA V et al.: High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial. Liver Int. (2003) 23:255-261.
40. WRIGHT M, FORTON D, MAIN J et al.: Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multi-centre, randomized, controlled trial. J. Virol. (2005) 12:58-66.
41. GRIEVE R, ROBERTS J, WRIGHT M et al.: Cost effectiveness of interferon (α) or peginterferon (α) with ribavirin for histologically mild hepatitis C. Gut (2006) in press.
42. ZEUZEM S, DIAGO M, GANE E et al.: Peginterferon α-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 127:1724-1732.
43. KRONENBERGER B, HERRMANN E, MICOL F et al.: Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology (2004) 40:1442-1449.
44. MAUSS S, ROCKSTROH JK: HCV/HIV-coinfection-is there a state of the art after APRICOT and RIBAVIC? J. Antimicrob. Chemother. (2005) 56:615-618.
45. ROCKSTROH J, MOCROFT A, SORIANO V et al.: Influence of hepatitis C virus on HIV-1 disease progression and response to highly active antiretroviral therapy. J. Infect. Dis. (2005) 192:992-1002.
46. EYSTER ME, DIAMONDSTONE LS, LIEN JM et al.: Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J. Acquir. Immune Defic. Syndr. (1993) 6:602-610.
47. ROCKSTROH JK, SPENGLER U, SUDHOP T et al: Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am. J. Gastroenterol. (1996) 91:2563-2568.
48. MOCROFT A, SORIANO V, ROCKSTROH J et al: Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 19:2117-2125.
49. QURISHI N, KREUZBERG C, LUCHTERS G et al: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 362:1708-1713.
50. CHUNG RT, ANDERSEN J, VOLBERDING P et al.: Peginterferon α-2a plus ribavirin versus interferon α-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. (2004) 351:451-459.
51. CARRAT F, BANI-SADR F, POL S et al.: Pegylated interferon α-2b versus standard interferon α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA (2004) 292:2839-2848.
52. TORRIANI FJ, RODRIGUEZ-TORRES M, ROCKSTROH JK et al.: Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. (2004) 351:438-450.
53. LAGUNO M, MURILLAS J, BLANCO JL et al.: Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS (2004) 18:F27-F236.
54. MAUSS S, VALENTI W, DEPAMPHILIS J et al.: Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS (2004) 18:F21-F25.
55. TOVO PA, LAZIER L, VERSACE A: Hepatitis B virus and hepatitis C virus infections in children. Curr. Opin. Infect. Dis. (2005) 18:261-266.
56. STEININGER C, KUNDI M, JATZKO G et al.: Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J. Infect. Dis. (2003) 187:345-351.
57. MOK J, PEMBREY L, TOVO PA, NEWELL ML: When does mother to child transmission of hepatitis C virus occur? Arch. Dis. Child. Fetal Neonatal Ed. (2005) 90:F156-F160.
58. RESTI M, AZZARI C, GALLI L et al.: Maternal drug use is a pre-eminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J. Infect. Dis. (2002) 185:567-572.
59. JAECKEL E, CORNBERG M, WEDEMEYER H et al.: Treatment of acute hepatitis C with interferon α-2b. N. Engl. J. Med. (2001) 345:1452-1457.
60. NOMURA H, SOU S, TANIMOTO H et al.: Short-term interferon-α therapy for acute hepatitis C: a randomized controlled trial. Hepatology (2004) 39:1213-1219.
61. GERLACH JT, DIEPOLDER HM, ZACHOVAL R et al.: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology (2003) 125:80-88.
62. NEUMANN UP, BERG T, BAHRA M et al.: Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation (2004) 77:226-231.
63. ABDELMALEK MF, FIRPI RJ, SOLDEVILA-PICO C et al.: Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. (2004) 10:199-207.
64. CHALASANI N, MANZARBEITIA C, FERENCI P et al.: Peginterferon α-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 41:289-298.
65. THOMAS RM, BREMS JJ, GUZMAN-HARTMAN G et al.: Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl. (2003) 9:905-915.
66. GISH RG: Treating HCV with ribavirin analogues and ribavirin-like molecules. J. Antimicrob. Chemother. (2006) 57:8-13.
67. LIN CC, PHILIPS L, XU C, YEH LT: Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J. Clin. Pharmacol. (2004) 44:265-275.
68. GISH RG, ARORA S, NELSON D: End-of-treatment response in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon a-2a. Abstracts of the 55th Annual Meeting of the American Association for the study of Liver Diseases (2004) Abstr. 519:388A.
69. GISH RG, ARORA S, NELSON D: Safety and efficacy of viramidine in combination with pegylated interferon α-2a for the treatment of hepatitis C in therapy-naive patients. Abstracts of the 39th Annual Meeting of the European Association for the Study of the Liver (2004) Abstr. 479:141-142.
70. DE FRANCESCO R, MIGLIACCIO G: Challenges and successes in developing new therapies for hepatitis C. Nature (2005) 436:953-960.
71. REISER M, HINRICHSEN H, BENHAMOU Y et al.: Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology (2005) 41:832-835.
72. CARRAT F, BANI-SADR F, POL S et al.: Pegylated interferon α-2b versus standard interferon α-2b plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA (2004) 292(23):2839-2848